A
20.71
-0.62 (-2.91%)
| Previous Close | 21.33 |
| Open | 21.42 |
| Volume | 1,706,483 |
| Avg. Volume (3M) | 1,993,957 |
| Market Cap | 2,863,323,136 |
| Price / Earnings (Forward) | 111.11 |
| Price / Sales | 6.80 |
| Price / Book | 7.87 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Profit Margin | -26.41% |
| Operating Margin (TTM) | 70.24% |
| Diluted EPS (TTM) | -1.24 |
| Quarterly Revenue Growth (YOY) | -29.60% |
| Total Debt/Equity (MRQ) | 108.23% |
| Current Ratio (MRQ) | 5.15 |
| Operating Cash Flow (TTM) | 61.15 M |
| Levered Free Cash Flow (TTM) | -6.46 M |
| Return on Assets (TTM) | -5.86% |
| Return on Equity (TTM) | -26.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Arrowhead Pharmaceuticals, Inc. | Mixed | Bullish |
AIStockmoo Score
1.6
| Analyst Consensus | 5.0 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.60 |
|
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 13.02% |
| % Held by Institutions | 77.19% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (HC Wainwright & Co., 286.29%) | Buy |
| Median | 60.00 (189.72%) | |
| Low | 38.00 (RBC Capital, 83.49%) | Buy |
| Average | 59.33 (186.48%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 19.77 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 02 Sep 2025 | 80.00 (286.29%) | Buy | 25.68 |
| Chardan Capital | 11 Aug 2025 | 60.00 (189.72%) | Buy | 17.21 |
| RBC Capital | 08 Aug 2025 | 38.00 (83.49%) | Buy | 16.42 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HAMILTON JAMES C | - | 25.68 | -15,000 | -385,200 |
| Aggregate Net Quantity | -15,000 | |||
| Aggregate Net Value ($) | -385,200 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 25.68 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HAMILTON JAMES C | Officer | 02 Sep 2025 | Automatic sell (-) | 15,000 | 25.68 | 385,200 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |